Peyronie's disease is a ®bromatosis of the tunica albuginea which affects up to 2% of men. Plaque development is believed to result, at least in part, from ®broblast proliferation and excess collagen deposition. Numerous oral and intralesional therapies have been used, including verapamil, colchicine and steroids. The purpose of this study was to investigate the in vitro effects of prostaglandin-E1 (PGE1), verapamil and colchicine on the proliferation rates of ®broblasts derived from Peyronie's disease tissue.
Introduction
Peyronie's disease affects 1 ± 3% of men and is the result of plaque formation in the tunica albuginea of the corpora cavernosa. 1, 2 This plaque, or scar, is thought to be caused by a ®brotic process involving ®broblast proliferation and excess collagen deposition. 3 ± 5 Plaque formation may lead to penile pain, marked penile curvature and sexual dysfunction. 6 ± 8 The precise mechanisms which lead to Peyronie's disease have not been fully elucidated at this time. Numerous theories regarding the etiology of Peyronie's have been proposed, including trauma, infection and autoimmune factors. 9 Somers et al, ®rst reported a model for the culture of ®broblasts from Peyronie's disease tissue, proposing that an activated form, or myo®broblast, may be responsible for alterations in extracellular matrix production. 10 The same author subsequently reported an increase in type III collagen in plaque tissue. 4 However, no single theory has been able to adequately explain the exact circumstances through which patients develop Peyronie's disease. Data from the study of similar ®brotic diseases such as Dupuytren's contracture have raised questions about the role of cytokines in the development of ®brosis. 3,11 ± 15 Biologically active peptides such as platelet-derived growth factor (PDGF), ®broblast growth factor (FGF), and transforming growth factor-beta (TGF-b) are known to play a role in collagen synthesis, while ®broblast growth factor (FGF) is thought to be a potent regulator of cell proliferation, differentiation and function. 16, 17 Furthermore, El-Sakka et al have shown an increase in TGF-b protein expression in Peyronie's disease. 18 Thus, it is apparent that alterations at the cellular and molecular level may indeed play an important role in the disease process. Despite this, our understanding of the basic pathways which lead to plaque formation has been lacking, in part, due to the absence of reliable models for the study of ®bromatoses.
Because the pathophysiology of Peyronie's disease is so poorly understood, there is no clear consensus on how it should be treated. Numerous conservative (oral and intralesional) therapies have been used in the treatment of Peyronie's disease, including verapamil, colchicine, steroids and alphainterferon. The effectiveness of these agents has not been clearly proven, therefore surgery remains the mainstay of de®nitive therapy in patients with persistent signi®cant penile curvature. We have developed a simple and ef®cient model for the culture and quanti®cation of proliferation of ®bro-blasts derived from Peyronie's tissue. The purpose of this study was to investigate the in vitro effects of a variety of biologic agents, such as prostaglandin E-1 (PGE 1 ), verapamil, colchicine and alpha-interferon, on the proliferation rates of ®broblasts derived from Peyronie's disease tissue.
Materials and methods

Patients
Patients with documented clinically signi®cant Peyronie's disease of greater than 12 months duration who were undergoing surgery for correction of penile curvature or penile prosthesis placement were enrolled according to an approved protocol.
Tissue acquisition
Specimens were excised from eight patients with Peyronie's disease. At the time of surgery, two tunical samples were taken from each patient, one from the plaque itself and one from an area of normal' tunica remote from the plaque. All fascial tissue was stripped from both specimens, which were, by design, partial thickness so that no corporal smooth muscle would be included. The plaque biopsy was a shave biopsy while the normal tunical tissue measured approximately 3 mm 2 in size. The specimens were placed immediately into transport medium (RPMI 10% fetal bovine serum, 10 mM HEPES, neomycinakanamycin) and transported directly to the laboratory. Adult foreskins were used as controls and were handled in the same manner.
Cell isolation and culture
Using sterile technique, the tissue was sharply divided into 1 mm 2 fragments. Fragments from normal and plaque tissue were placed into separate 50 ml sterile centrifuge tubes containing alpha-MEM (JRH Scienti®c) supplemented with type H collagenase (0.5 mgaml). The cells were then incubated overnight at 37 C in 5% humidi®ed CO 2 . The cells and tissue fragments were collected by centrifugation and washed in fresh tissue culture media. Pieces of digested tissue were placed into 25 cm 2 sterile tissue culture¯asks along with cells from the pellet and incubated in tissue culture medium (alpha-MEM 10% fetal bovine serum, 1% glutamine, neomycinakanamycin) at 37 C in 5% CO 2 . Tissue culture media was changed at 48 h and every 5 ± 6 days thereafter. Once they had formed conuent monolayers, the cells were harvested using trypsinaEDTA. After washing, cells for continuous cultures were split 1 : 3 and grown to con¯uence. At various passages, cells were stored in RPMI 15% fetal bovine serum 7.5% DMSO at minus 90 C.
Cell characterization
To determine cell type, expression of intermediate ®lament proteins and actin-containing micro®laments was ascertained by indirect immunouorescence. Cells were cultured into sterile multi-chamber slides (Labtek, CA) and grown until nearly con¯uent by inverted microscopy. Slides were washed three times with cold PBS, and cells were ®xed using either 100% cold methanol (4 C) or 2% paraformaldehyde (15 min at 4 C, freshly prepared in PBS), followed by washing in cold PBS (4 C) and cell permeabilization (100% cold methanol). Slides were then washed three times with cold PBS. Individual chambers were incubated with antibodies to vimentin (DAKO), cytokeratin or smooth muscle-speci®c actin (DAKO). Mouse isotype antibodies were used as controls. Primary antibodies were incubated at 4 C for 60 min; they were then washed three times with cold PBS containing 5% BSA and incubated with secondary antibody (FITCgoat±anti-mouse Ig, ®nal dilution 1 : 20, Becton Dickinson) for 30 min Nuclei were counterstained using propidium iodide (1 mgaml) after washing again three times with cold PBSa5% BSA. Anti-fade solution was added and slides were coverslipped. Slides were then viewed using a Zeiss Axioscope¯uorescence microscope with epi¯uorescence illumination. Human foreskin ®broblasts at early passage were used as control cells.
Biologic agents
Prostaglandin E 1 was obtained in the form of Caverject TM (Pharmacia, MI), a lysophilized powder, and directly diluted to the desired concentration in culture media (RPMI 10% FCS). Verapamil was obtained in the form of an injectable solution, 5 mg in 2 ml sterile normal saline (2.5 mgaml) and directly diluted to the desired concentration in culture media. Colchicine was obtained in the form of a solution in the concentration of 5 mgaml and diluted as needed into culture media. Interferon a2b (Schering-Plough, Madison NJ) was obtained in solution in a concentration 3 6 10 6 units per ml.
Cell proliferation
Determination of cell growth rates was performed using the Vybrant TM MTT Cell Proliferation Assay (Molecular Probes Inc., Eugene, OR). 19 The experimental protocol found in the manufacturer's product information sheet was adhered to with some select modi®cations. Con¯uent cells in each parent culture were harvested, counted in a hemocyto-meter, and diluted in culture media (RPMI 10% fetal bovine serum) to a concentration of 5 6 10 4 cells per ml. Cells were then delivered to the wells of a standard 96-well microplate in 100 ml volumes for a ®nal cell density of 5 6 10 4 cells per well. PGE 1 , verapamil, colchicine and alpha-interferon were then diluted to various concentrations in culture media as described above and delivered into the wells in 100 ml volumes for a ®nal volume of 200 ml per well. Cells were plated in triplicate. Cells were then incubated at 37 C in a humidi®ed atmosphere of 5% CO 2 .
At 24, 48, 72 and 96 h, the MTT assay was performed. Firstly, the media was removed and replaced with 200 ml of fresh culture medium (Phenol-free RPMI 10% fetal bovine serum). We then dissolved 50 mg MTT in 10 ml PBS and ®ltered the solution with a sterile 0.22 mm ®lter (Costar, Cambridge, MA). This served as a 12 mM MTT stock solution. Deviation from the suggested protocol was necessary because of incomplete dissolution of some particulate matter when the MTT was dissolved directly in PBS alone. Having prepared the stock solution, we then added 10 ml of the 12 mM MTT solution to each microplate well. The cells were again incubated for 4 h. Following this, 10 ml of 0.01 M HCl was added to 1 g SDS. The solution was mixed by gentle inversion. HCl ± SDS (100 ml) solution was then added to each well, mixing with the pipette. The microplate was then incubated overnight in a 37 C humidi®ed chamber as before. Absorbance was the measured at 595 nm using a microplate reader (Fischer Biotech BT 2000 Microkinetics Reader).
Results
Cell culture and characterization
To date, six viable cell lines have been established from Peyronie's disease plaque and ®ve from normal tunical tissue. Cell lines have also been established from foreskin tissue. All cell lines exhibited excellent linear growth in culture media alone. Based on immunohistochemical criteria (vimentin positive, smooth-muscle actin positive, cytokeratin and desmin negative), these cells represent myo®bro-blasts. No difference in the staining pattern was seen between plaque and normal tunica-derived cells.
Cell proliferation
The effects of the various agents on plaque-derived ®broblasts are reported in Figures 1 ± 4 . Inhibition is expressed as the percentage reduction in optical density (OD) on spectrophotometry at 96 h when compared to control cells, that is, cells cultured in culture medium alone without biologic agents. Maximum inhibition occurred at 96 h in all cases. Culture of plaque ®broblasts with PGE 1 resulted in inhibition of growth of 72 AE 15% at 10 mgaml, 60 AE 11% at 7.5 mgaml and 32 AE 19% at 5 mgaml. No signi®cant effect was seen at 1 and 0.1 mgaml. Culture with verapamil resulted in a 75% inhibition of cells at 1000 mgaml and 74 AE 15% at 100 mgaml. No signi®cant effect was seen at 50, 25 and 10 mgaml, respectively. Culture with alpha-IFN resulted in 40% inhibition at a concentration of 10 5 IUaml, 36% at 10 4 IUaml, and 17 AE 5% at 10 3 IUaml. Culture with colchicine resulted in a 58 AE 19% growth inhibition at 2.5 mgaml and 58 AE 24% at 0.5 mgaml.
Discussion
Historically, a number of agents, both oral and intralesional, have been used to treat Peyronie's disease.
However, to date, there exists no robust data that is randomized and placebo-controlled that clearly identi®es an agent as a reliable medical management for Peyronie's disease. Colchicine, a potent antiin¯ammatory medication that has been in use for many years, primarily for the treatment of gout, has also been used for the treatment of Peyronie's disease. This is based, at least in part, on the theory that Peyronie's disease involves an in¯ammatory phase prior to the initiation of ®brosis. 20 Colchicine binds to tubulin, blocking mitosis through interference with the mitotic spindle (micro-tubules), and inhibits the activities of polymorphonuclear monocytes (PMN). 21 Phagocytosis, a key function in the in¯ammatory response, also depends on an intact microtubular system. 22 Colchicine also interferes with the movement of collagen from cell to cell, decreases the activity of collagen processing enzymes, and stimulates the production of collagenase. 23 For these reasons and others, colchicine has been advocated in the treatment of in¯ammatory and ®brotic diseases. 24 Our results suggest that colchicine has a signi®cant inhibitory effect on the proliferation of Peyronie's ®broblasts in vitro.
Another conservative therapy, which has been used in Peyronie's disease, is the use of intralesional verapamil. Calcium channel blockers have been shown to inhibit synthesis and secretion of several components of extracellular matrix, including collagen, glycosoaminoglycans (GAG) and ®bronec-tin. 25 Verapamil is also reported to suppress the activity of TGF-b and increase collagenase. 25 In a single-center, non placebo-controlled trial in 1997, Levine reported a signi®cant response to intralesional verapamil, with reduction in penile pain and deformity, and improvement of sexual function. 26 While others have reported similar ®ndings in select subsets of patients, there are reports that contradict these ®ndings. 25, 27 Our ®ndings suggest that proliferation of Peyronie's ®broblasts is markedly impaired by verapamil, even at low doses. A similar study conducted on urothelial cells by Wolf et al 28 also demonstrated that urothelial cell proliferation was impaired at higher doses (1000 mgaml), but was increased at low dose (5 mgaml).
As previously mentioned, recent studies on the physiology of wound healing and ®brosis suggest an important role for cytokines. Interferons are one class of cytokines which have been investigated. In contrast to the stimulatory effects of most cytokines, interferons are anti-®brotic, turning off collagen gene expression and suppress collagen production by ®broblasts. 29, 30 Duncan et al, reported that interferons also inhibit proliferation of ®broblasts, as well as increase GAG and collagenase production. 31 Additionally, Oreffo et al; found that alphainterferon had an inhibitory effect on proliferation of in vitro ®broblasts derived from bone marrow. 32 One study proposed that alpha-interferon interferes with the synthesis of bFGF, which in turn, leads to growth inhibition of melanoma cells in vitro.
Several clinical trials using intralesional interferons have been borne out of these ®ndings, the results of which are mixed. Wegner et al ®rst found an effect in early, non calci®ed lesions, but then later published an article stating that interferonalpha-2b is not effective. 34, 35 Judge et al, found a minimal positive objective effect on patients with smaller plaques, while Lue argued against the effectiveness of local interferon in 1998. 36, 37 Ahuja et al, reported a signi®cant improvement in pain and curvature in their 1999 article. 38 Our ®ndings suggest that alpha-interferon has a signi®cant inhibitory effect on the proliferation of ®broblasts in vitro.
Prostaglandin E 1 is a well-known mediator of second messenger pathways for various cellular functions. Its widespread use as a vasoactive agent for intracavernosal therapy of erectile dysfunction is well documented. PGE 1 induces production of cAMP which leads to smooth muscle relaxation. More relevant to the current discussion, however, is the research by Moreland et al, who reported that PGE 1 suppresses the induction of collagen synthesis by suppressing TGF-b 1 mRNA. 39, 40 Furthermore, TGF-b 1 has been shown to induce ®brosis in the corpora cavernosa of rabbits. These ®ndings, in addition to those of El-Sakka showing an association between increased TGF-b 1 and Peyronie's disease, 18 provide a rationale for the investigation of PGE 1 as a modulator cell proliferation in Peyronie's disease. Our ®ndings indicate that PGE 1 inhibits the proliferation of Peyronie's ®broblasts in vitro.
The MTT assay is limited in its scope, particularly as it solely measures active cells, not accounting for dead or dying cells, which have ceased Figure 4 Percentage inhibition of ®broblasts using various doses of colchicine. Percentage inhibition is de®ned as the percentage reduction in optical density (OD) on spectrophotometry at 96 h when compared to control cells (plaque-derived ®broblasts in culture medium alone). mitochondrial metabolism. Therefore, it fails to differentiate between nonproliferating cell and dead cells. The data presented here are believed to represent cells that are viable but non-active; however, some of the compounds at some of the does may in fact the catatonic. Current investigation is aimed at performing viability studies to answer this question. Further investigation is also currently under way evaluating the response of foreskin and normal tunica-derived ®broblasts to the above agents.
In summary, therefore, a reliable in vitro assay has been developed to evaluate the biologic response of Peyronie's plaque-derived ®broblasts to a variety of agents. These data suggest that all of the agents evaluated have a signi®cant effect upon cell proliferation and, therefore, there is a rational basis in the future for exploring their utility in the management of patients with Peyronie's disease, preferably in a randomized, placebo-controlled fashion.
